Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté (STeF-BFC)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02852993
Recruitment Status : Completed
First Posted : August 2, 2016
Last Update Posted : August 2, 2016
Sponsor:
Collaborators:
Centre Hospitalier Universitaire Dijon
Etablissement Français du Sang
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Besancon

Brief Summary:

Red blood cell transfusion (RBC) is the main symptomatic treatment for severe anemia. RBC transfusion has proven its efficacy regarding mortality and morbidity, but it is not without side effects. The infectious side effects of transfusion are largely considered under control, non-infectious side effects are taking center stage. Seeking explanations for the beneficial and deleterious effects of RBC transfusions is necessary to ensure the safe and optimal use of this precious resource.

The investigators aim to study the impact of donor and RBC characteristics on patient survival.


Condition or disease
Erythrocyte Transfusion for All Conditions

Layout table for study information
Study Type : Observational
Actual Enrollment : 16099 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Survival After Blood Transfusion in the French Administrative Regions of Burgundy and Franche-Comté
Study Start Date : September 2013
Actual Primary Completion Date : June 2015
Actual Study Completion Date : June 2015

Resource links provided by the National Library of Medicine


Group/Cohort
Transfused patients
A cohort of patients receiving erythrocyte transfusion for the first time at the CHU Besançon or CHU Dijon during the study period.



Primary Outcome Measures :
  1. Survival [ Time Frame: 12 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
The eligible patients consisted of all adult patients transfused for the first time (defined as patients with no known history of RBC unit use in the transfusion register), at the university hospitals of Besançon or Dijon, between January 2007 and December 2011.
Criteria

Inclusion Criteria:

  • Aged 18 and over
  • Erythrocyte Transfusion between 2007 and 2011
  • Performed at the University Hospital of Besançon or Dijon

Exclusion Criteria:

  • Transfusion of any blood product prior to January 1st, 2007

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02852993


Locations
Layout table for location information
France
Centre d'Investigation Clinique, CHU de Besançon
Besançon, France, 25030
Département d'information Médicale, CHU Dijon
Dijon, France, 21079
Sponsors and Collaborators
Centre Hospitalier Universitaire de Besancon
Centre Hospitalier Universitaire Dijon
Etablissement Français du Sang
Investigators
Layout table for investigator information
Principal Investigator: Maxime Desmarets, MD, PhD Centre d'Investigation Clinique; CHU Besançon
Publications of Results:
Layout table for additonal information
Responsible Party: Centre Hospitalier Universitaire de Besancon
ClinicalTrials.gov Identifier: NCT02852993    
Other Study ID Numbers: P/2013/176
First Posted: August 2, 2016    Key Record Dates
Last Update Posted: August 2, 2016
Last Verified: July 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Keywords provided by Centre Hospitalier Universitaire de Besancon:
Erythrocyte Transfusion
Survival